Ocular Therapeutix (Ocular Therapeutix) Forward Dividend Yield %

: 0.00% (As of Today)

View and export this data going back to 2014. Start your Free Trial

As of today (2024-04-16), the Forward Annual Dividend Yield of Ocular Therapeutix is 0.00%.

As of today (2024-04-16), the Trailing Annual Dividend Yield of Ocular Therapeutix is 0.00%.

OCUL's Forward Dividend Yield % is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.595
* Ranked among companies with meaningful Forward Dividend Yield % only.

Ocular Therapeutix's Dividends per Share for the three months ended in Dec. 2023 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison

For the Biotechnology subindustry, Ocular Therapeutix's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ocular Therapeutix Forward Dividend Yield % Distribution

For the Biotechnology industry and Healthcare sector, Ocular Therapeutix's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Ocular Therapeutix's Forward Dividend Yield % falls into.

Ocular Therapeutix Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

Ocular Therapeutix (NAS:OCUL) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Ocular Therapeutix Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Ocular Therapeutix's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Ocular Therapeutix (Ocular Therapeutix) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocular Therapeutix Inc (NAS:OCUL) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

0OT:Germany 0OT:Germany

Address

24 Crosby Drive, Bedford, MA, USA, 01730

Website

https://www.ocutx.com

Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Ocular Therapeutix aims to offer medication to replace the existing eye-drop therapy regimen, with the aim of lasting weeks or months with a one-time product application. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.

Executives

Summer Road Llc	10 percent owner	207 6TH STREET, WEST PALM BEACH FL 33401
Antony C. Mattessich	director	C/O OCULAR THERAPEUTIX, INC., 34 CROSBY DR., SUITE 105, BEDFORD MA 01730
Adrienne L Graves	director	125 STONE MOUNTAIN CIRCLE, NAPA CA 94558
Rabia Gurses Ozden	officer: Chief Medical Officer	C/O AKOUOS, INC., 645 SUMMER STREET SUITE 200, BOSTON MA 02210
Philip C. Strassburger	officer: General Counsel	24 CROSBY DRIVE, BEDFORD MA 01730
Donald Notman	officer: Chief Financial Officer	C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730
Christopher G White	officer: Chief Business Officer	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Jeffrey S. Heier	director	C/O OCULAR THERAPEUTIX, INC., 34 CROSBY DR., SUITE 105, BEDFORD MA 01730
Merilee Raines	director	IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
Lindstrom Richard L Md	director	2811 WESTWOOD PL, WAYZATA MN 55391
Opaleye Management Inc.	10 percent owner	ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108
Patricia Kitchen	officer: Chief Operations Officer	C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730
Leslie J. Williams	director	C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730
Seung Suh Hong	director	C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730
Amarpreet Sawhney	director, 10 percent owner, officer: President and CEO	C/O OCULAR THERAPEUTIX, INC., 36 CROSBY DRIVE, SUITE 101, BEDFORD MA 01730